High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition
Summary: Reoccurring/high-risk neuroblastoma (NB) tumors have the enrichment of non-RAS/RAF mutations along the mitogen-activated protein kinase (MAPK) signaling pathway, suggesting that activation of MEK/ERK is critical for their survival. However, based on preclinical data, MEK inhibitors are unli...
Main Authors: | Jinyang Cai, Sheeba Jacob, Richard Kurupi, Krista M. Dalton, Colin Coon, Patricia Greninger, Regina K. Egan, Giovanna T. Stein, Ellen Murchie, Joseph McClanaghan, Yuta Adachi, Kentaro Hirade, Mikhail Dozmorov, John Glod, Sosipatros A. Boikos, Hiromichi Ebi, Huaixiang Hao, Giordano Caponigro, Cyril H. Benes, Anthony C. Faber |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-07-01
|
Series: | Cell Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S221112472200897X |
Similar Items
-
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
by: Yuta Adachi, et al.
Published: (2021-10-01) -
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA
by: Carter K. Fairchild, et al.
Published: (2021-05-01) -
SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition
by: Xianning Lai, et al.
Published: (2023-12-01) -
Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
by: Chris Jopling, et al.
Published: (2007-12-01) -
Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2
by: Julia Taylor, et al.
Published: (2023-06-01)